Alexandria Real Estate Equities/$ARE

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Alexandria Real Estate Equities

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.

Ticker

$ARE

Primary listing

NYSE

Employees

552

ARE Metrics

BasicAdvanced
$9.6B
-
-$2.47
1.32
$5.28
9.49%

What the Analysts think about ARE

Analyst ratings (Buy, Hold, Sell) for Alexandria Real Estate Equities stock.

Bulls say / Bears say

In July 2025, Alexandria executed the largest life science lease in its 31-year history by signing a 16-year, 466,598 RSF build-to-suit agreement at its Campus Point Megacampus, highlighting robust tenant demand for its flagship innovation ecosystem. (PR Newswire)
Alexandria reported that 84% of its leasing activity over the past 12 months stemmed from existing tenants, supporting an average tenant retention rate exceeding 80% over the past five years, which underpins stable cash flows. (Investor Relations)
The company maintains a liquidity reserve of $4.6 billion and among the longest debt maturities in the S&P 500 REIT cohort, providing balance sheet flexibility to fund development and capital recycling strategies. (Stocktitan)
Alexandria reduced its full-year 2025 adjusted FFO guidance to $9.16–9.36 per share from $9.23–9.43, citing softer leasing activity, a signal of potential revenue headwinds. (Reuters via Investing.com)
Same-property net operating income declined 5.4% year-over-year (cash basis) in 2Q25 due to lease expirations in key markets, highlighting pressures on underlying property performance. (Investor Relations)
ARE shares traded 47.3% below their 52-week high as of May 21, 2025, underperforming peers amid investor concerns over growth visibility in the life science REIT sector. (MarketWatch)
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2025.

ARE Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ARE Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ARE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs